Status:
ACTIVE_NOT_RECRUITING
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
Lead Sponsor:
Eli Lilly and Company
Conditions:
Prostatic Neoplasms
Neoplasm Metastasis
Eligibility:
MALE
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse. Participation may last approximately 60 months.
Eligibility Criteria
Inclusion
- Adenocarcinoma of the prostate (as the predominant histology)
- High-risk metastatic hormone-sensitive prostate cancer. High risk is defined as:
- Greater than or equal to (≥)4 bone metastases by bone scan and/or
- ≥1 visceral metastases by computed tomography or magnetic resonance imaging
- Must have initiated androgen deprivation therapy (ADT) with luteinizing hormone-releasing hormone (LHRH) agonist/antagonist or bilateral orchiectomy prior to randomization. Up to 3 months of ADT prior to randomization is permitted with or without first-generation anti-androgen.
- Adequate organ function
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Exclusion
- Prior treatment with abemaciclib or any other cyclin dependent kinase 4 and 6 (CDK4 \& 6) inhibitor
- Development of metastatic prostate cancer in the context of castrate levels of testosterone
- Received any prior systemic therapy for metastatic prostate cancer (including investigational agents), except for ADT and first-generation anti-androgen
- Clinically significant cardiovascular disease as evidenced by myocardial infarction, arterial thrombotic events, or severe/unstable angina in the past 6 months, or New York Heart Association Class II to IV heart failure
- History of syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin, or sudden cardiac arrest. Chronic and hemodynamically stable atrial arrhythmia well-controlled on medical therapy is permitted
- Uncontrolled hypertension
- Clinically active or chronic liver disease, moderate/severe hepatic impairment
- Known untreated central nervous system (CNS) metastasis. Participants with a history of treated brain metastases are eligible if stable for at least 8 weeks prior to randomization and off corticosteroid for at least 2 weeks prior to randomization
Key Trial Info
Start Date :
April 14 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2027
Estimated Enrollment :
925 Patients enrolled
Trial Details
Trial ID
NCT05288166
Start Date
April 14 2022
End Date
October 1 2027
Last Update
June 27 2025
Active Locations (266)
Enter a location and click search to find clinical trials sorted by distance.
1
Arizona Oncology Associates, P.C. - HOPE
Prescott, Arizona, United States, 86301
2
Arizona Oncology Associates, P.C. - HOPE
Prescott Valley, Arizona, United States, 86314
3
The University of Arizona Cancer Center - North Campus
Tucson, Arizona, United States, 85719
4
Genesis Cancer and Blood Institute
Hot Springs, Arkansas, United States, 71913